Examining FDA’s Generic Drug and Biosimilar User Fee Programs Video of Examining FDA’s Generic Drug and Biosimilar User Fee Programs. Witnesses Mr. Allan Coukell Senior Director, The Pew Charitable Trusts, Health Programs Witness Statement Truth in Testimony and CV Mr. David Gaugh Senior Vice President of Sciences and Regulatory Sciences, Association for Accessible Medicines Witness Statement Truth in Testimony and CV Ms. Kay Holcombe Senior Vice President of Science Policy, Biotechnology Industry Organization Witness Statement Truth in Testimony and CV Mr. Bruce A. Leicher Chair, a Division of the Association for Accessible Medicines, The Biosimilars Council Witness Statement Truth in Testimony and CV Ms. Juliana Reed Immediate Past President, The Biosimilars Forum Witness Statement Truth in Testimony and CV Dr. Janet Woodcock M.D. Director, Food and Drug Administration, Center for Drug Evaluation and Research Witness Statement Truth in Testimony and CV Text of Legislation H.R. 749, Lower Drug Costs through Competition Act Documents Hearing Notice Background Memo Opening Statement – Full Committee Chairman Greg Walden Opening Statement – Health Subcommittee Chairman Michael C. Burgess Hearing Attendance Preliminary Transcript Opening Statement – Full Committee Ranking Member Frank Pallone, Jr. Document for the Record – Rep. Long – FTC Article Related Items HEARING: #SubHealth to Look at User Fees NEXT WEEK Subcommittees Health (115th Congress) Health hearing